GSK2982772 capsule
Sponsors
GlaxoSmithKline
Conditions
Autoimmune DiseasesInflammatory Bowel Diseases
Phase 1
A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects
CompletedNCT02302404
Start: 2015-01-06End: 2016-03-05Updated: 2017-05-09
A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects
CompletedNCT03305419
Start: 2017-10-11End: 2018-10-15Updated: 2023-10-10